• Case Reports
• ·
• Research Projects
• ·
• Physician Resources

This 2006 interview is an excellent overview of the early science of cannabinoid medicine. Dr. Mechoulam is recognized as one of the world’s experts on cannabinoid-based medicine. In addition to his groundbreaking discoveries, he has authored hundreds of scientific papers on his cannabinoid research as well as a book, Cannabinoids as Therapeutic Agents, which provides an early review of the research in this area.  →

Did you know that smoking cannabis is a rare trigger of acute myocardial infarction and may pose a health risk to patients with established coronary artery disease and perhaps to individuals with multiple coronary risk factors?  →

If Marijuana were unknown, and bio-prospectors were suddenly to find it in some remote mountain crevice, its discovery would no doubt be hailed as a medical breakthrough. Scientists would praise its potential for treating everything from pain to cancer and marvel at its rich pharmacopoeia; many of whose chemicals mimic vital molecules in the human body.  →

As reported in a 2006 issue of Molecular Pharmacology: “Compared to currently approved drugs prescribed for the treatment of Alzheimer’s disease, THC is a considerably superior inhibitor of Aβ aggregation, and this study provides a previously unrecognized molecular mechanism through which cannabinoid molecules may directly impact the progression of this debilitating disease.”  →

Can CBD counteract adverse effects of excessive THC? In this 2010 issue of the journal Neuropsychopharmacology, they showed that pretreatment with CBD prevented the acute induction of psychotic symptoms by D-9-tetrahydrocannabinol. D-9-THC and CBD can have opposite effects on regional brain function, which may underlie their different symptomatic and behavioral effects, and CBD’s ability to block the psychotogenic effects of D-9-THC.  →

The years 2003 – 2008 showed a remarkable increase in publications on cannabidiol mainly stimulated by the discovery of its anti-inflammatory, anti-oxidative and neuroprotective effects. These studies have suggested a wide range of possible therapeutic effects of cannabidiol on several conditions, including Parkinson’s disease, Alzheimer’s disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer.  →

In this review article published in the German Medical Association’s official journal Deutsches Ärzteblatt, the authors present the current state of knowledge on the therapeutic application of cannabinoid medications. This article was translated from the original German and recently made available to the public.  →

The U.S. Circuit Court of Appeals in Washington, D.C., has agreed to hear Americans for Safe Access vs. Drug Enforcement Administration, which challenges the federal classification of marijuana as a Schedule I drug. Oral arguments are scheduled to start October 16, 2012. The Schedule I classification is one of the biggest arguments against medical marijuana nationwide because Schedule I drugs are defined as having no accepted medical use. Not only is this not accurate, but classification as Schedule I makes it difficult to complete well designed research studies on the benefits and limitations of cannabis as medicine.  →